Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer
This study is ongoing, but not recruiting participants.
Study NCT00019474 Information provided by National Cancer Institute (NCI)
First Received: July 11, 2001 Last Updated: February 6, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Extrahepatic Bile Duct Cancer
Gastric Cancer
Gastrointestinal Carcinoid Tumor
Liver Cancer
Pancreatic Cancer
Small Intestine Cancer
Additional conditions recognized in this trial
Bile Duct Neoplasms
Carcinoid Tumor
Duodenal Neoplasms
Gastrointestinal Neoplasms
Ileal Neoplasms
Intestinal Neoplasms
Jejunal Neoplasms
Liver Neoplasms
Malignant Carcinoid Syndrome
Pancreatic Neoplasms
Stomach Neoplasms
More general conditions related to this trial
Adenocarcinoma
Bile Duct Diseases
Biliary Tract Diseases
Biliary Tract Neoplasms
Carcinoma
Digestive System Diseases
Digestive System Neoplasms
Duodenal Diseases
Endocrine Gland Neoplasms
Endocrine System Diseases
Gastrointestinal Diseases
Ileal Diseases
Intestinal Diseases
Jejunal Diseases
Liver Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Pancreatic Diseases
Stomach Diseases
Interventions listed in this trial
filgrastim
recombinant interferon alfa
fluorouracil
hydroxyurea
Additional drug interventions recognized in this trial
Interferon Alfa-2a
Interferon Type I, Recombinant
Interferon-alpha
Interferons
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antisickling Agents
Antiviral Agents
Enzyme Inhibitors
Growth Inhibitors
Growth Substances
Hematologic Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Albert Einstein College of Medicine of Yeshiva University
National Cancer Institute (NCI)
Back to top of Main Content
